(Q36780156)

16 August 2017

1 reference

title

Use of viral vectors for the development of vaccines (English)

1 reference

16 August 2017

Matthias Liniger

1

1 reference

16 August 2017

Armando Zuniga

series ordinal

2

1 reference

16 August 2017

Hussein Y Naim

series ordinal

3

1 reference

16 August 2017

language of work or name

1 reference

1 April 2007

1 reference

Expert Review of Vaccines

16 August 2017

1 reference

16 August 2017

6

1 reference

16 August 2017

2

1 reference

16 August 2017

255-266

1 reference

A review of vaccine research and development: the human immunodeficiency virus (HIV).

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

A review of human vaccine research and development: malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Adjuvant and antigen delivery properties of virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

HIV vaccines: new frontiers in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Replication-defective viruses as vaccines and vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Current progress in the development of HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Recombinant viruses as vaccines against viral diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Intranasal delivery of vaccines against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Viral gene therapy strategies: from basic science to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Genetic content and evolution of adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Adenoviral strategies for the gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Adenovirus: from foe to friend.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Rational design of gene-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Adenoviral vectors for mucosal vaccination against infectious diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Development of nonhuman adenoviruses as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Pox viral vaccine approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Poxvirus vectors: orphaned and underappreciated

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

New hope for an AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

MVA as a vector for vaccines against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Alphavirus vectors for gene expression and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Alphavirus expression vectors and their use as recombinant vaccines: a minireview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Alphavirus vectors for vaccine production and gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Current development of adeno-associated viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Adeno-associated virus vectors: potential applications for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

The controversial role of adenoviral-derived vectors in gene therapy programs: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Recent advances in recombinant adeno-associated virus vector production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Downstream processing of viral vectors and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Current issues in adeno-associated viral vector production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Reverse Genetics Meets the Nonsegmented Negative-Strand RNA Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Measles virus matrix protein specifies apical virus release and glycoprotein sorting in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Nonsegmented negative-strand viruses as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Viral vectors as potential HIV-1 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Yellow fever 17D as a vaccine vector for microbial CTL epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Expression of foreign protein epitopes at the surface of recombinant yellow fever 17D viruses based on three-dimensional modeling of its envelope protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Viral vectors for malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Replication-defective herpes simplex virus vectors for gene transfer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Development and application of herpes simplex virus vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Molecular imaging of gene therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Amplicon vectors as outstanding tools to study and modify cognitive functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Expression of the human immunodeficiency virus gag gene products by a replication-incompetent herpes simplex virus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.2.255

21 January 2018

Identifiers

DOI

10.1586/14760584.6.2.255

1 reference

16 August 2017

1 reference